For Media

Argos Therapeutics, Inc. is developing fully personalized immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform that we believe can tackle a wide range of cancers and infectious diseases.

906813904383903275901980901694899688899175898007897680896533fa07015d-74bf-4390-b3ae-89820091286676af8a64-d49d-4617-b3fa-cf90bbb0946a446f7637-40b6-4ea2-a260-4fcbe1edbd9387430855-818e-410b-b822-46d653a677b2031c716e-85d6-489d-a2f6-78221947b25f4fd4a0fd-37be-408b-81e5-604bed3904583fa1a147-e1cb-4a64-858b-4ad8d98b53e9cf888164-105c-4892-b54c-2b9c1dae8f154bee333d-e3c1-4dda-adcb-769304e84ff224ee5339-94fc-49eb-a427-938e845d59ddARGS_News_2016_9_1_General_Releases.pdfARGS_News_2016_8_10_General_Releases.pdfARGS_News_2016_8_4_General_Releases.pdfARGS_News_2016_7_28_General_Releases.pdfARGS_News_2016_7_27_General_Releases.pdfARGS_News_2016_7_14_General_Releases.pdfARGS_News_2016_7_11_General_Releases.pdfARGS_News_2016_6_29_General_Releases.pdfARGS_News_2016_6_27_General_Releases.pdfARGS_News_2016_6_15_General_Releases.pdf12228273451170212167116321308412574113051099713475123456789102016-9-1T16:5:0-4:02016-8-10T16:5:0-4:02016-8-4T8:0:0-4:02016-7-28T9:22:56-4:02016-7-27T16:6:11-4:02016-7-14T8:30:0-4:02016-7-11T8:0:0-4:02016-6-29T8:0:0-4:02016-6-27T8:0:0-4:02016-6-15T8:0:0-4:0987560983965982921981713981500979564978849977562977142975804General ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesArgos Therapeutics to Participate in 23rd Annual NewsMakers in the Biotech Industry ConferenceArgos Therapeutics Reports Second Quarter 2016 Financial Results and Recent Operational HighlightsArgos Therapeutics to Host Second Quarter 2016 Financial Results Conference Call on Wednesday, August 10, 2016Argos Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock and WarrantsArgos Therapeutics Announces Proposed Public Offering of Common Stock and WarrantsArgos Therapeutics Announces First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in the Treatment of HIVDr. Richard D. Katz Joins Argos Therapeutics as Chief Financial OfficerArgos Therapeutics Announces Closing of $29.8 Million Second Tranche of March 2016 FinancingArgos Therapeutics Added to the Russell 2000® IndexArgos Therapeutics Enters into Strategic Research Agreement with Adaptive Biotechnologies1461461461461461461461461461462016201620162016201620162016201620162016No Error0

Argos Therapeutics to Participate in 23rd Annual NewsMakers in the Biotech Industry Conference
Read more

Argos Therapeutics Reports Second Quarter 2016 Financial Results and Recent Operational Highlights
Read more

Argos Therapeutics to Host Second Quarter 2016 Financial Results Conference Call on Wednesday, August 10, 2016
Read more

Argos Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock and Warrants
Read more

Argos Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
Read more

Argos Therapeutics Announces First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in the Treatment of HIV
Read more

Dr. Richard D. Katz Joins Argos Therapeutics as Chief Financial Officer
Read more

Argos Therapeutics Announces Closing of $29.8 Million Second Tranche of March 2016 Financing
Read more

Argos Therapeutics Added to the Russell 2000® Index
Read more

Argos Therapeutics Enters into Strategic Research Agreement with Adaptive Biotechnologies
Read more